First AD

Second AD

Lana Pine is the editor of HCPLive Rheumatology. She is an experienced editor and technical writer with a demonstrated history of working in the banking and publishing industries. In her free time, she enjoys cooking, yoga, listening to podcasts, and drawing. She can be reached via email at LPine@mjhlifesciences.com.

 examined pharmacy claims data from Germany and France, focusing on adult patients with inflammatory bowel disease (IBD) who initiated treatment with ABP 501, an adalimumab 

, between October 2018 and March 2020. The study assessed treatment persistence, adherence, and switching patterns for two groups: adalimumab-naïve patients and adalimumab-experienced patients.

Test your knowledge of ABP 501 with this quiz:

Over 70% of patients persisted on ABP 501 after 12 months

Switching patterns were consistent between countries

Approximately 50% of patients remained on ABP 501 after 12 months, with varied switching patterns

Adherence rates were higher in ADA-experienced patients

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Biosimilars

Quizzes

Test your knowledge of treatment persistence, adherence, and switching patterns of adalimumab biosimilar ABP 501 between adalimumab-naïve patients and adalimumab-experienced patients.

Biosimilars Quiz: Adalimumab Biosimilar ABP 501 Adherence, Switching Patterns